Results 161 to 170 of about 1,716,154 (283)

Real-world prevalence and prognostic significance of hepatotoxicity after chimeric antigen receptor T-cell therapy. [PDF]

Br J Haematol
Hollnberger J, Richardson T, Gödel P, Leutiger J, Schumacher JC, Schiestel S, Allhoff B, Scheid C, Holtick U, Neumann-Haefelin C, Allo G, Kasper P.   +11 more
europepmc   +1 more source

Cell and Gene Therapies Manufacturing Challenges and Integrated Good Manufacturing Practices Solutions: A Lifecycle Perspective

Biotechnology and Bioengineering, EarlyView.
Lifecycle perspective on cell and gene therapy manufacturing challenges and enabling GMP solutions. ABSTRACT Cell and gene therapies (CGTs) are revolutionizing modern medicine; however, making these advanced medicines scalable and readily available to commercial manufacturers worldwide is a major challenge. The number of approved CGT products continues
Rajath Samaga, Udisha Singh, Sachin Dattram Pawar   +2 more
wiley   +1 more source

The dilemma after chimeric antigen receptor T-cell therapy - to transplant or not? [PDF]

Haematologica
Jacoby E, Bielorai B.
europepmc   +1 more source

Chimeric antigen receptor T-cells in multiple myeloma: Present and future [PDF]

This is a brief summary of various general contemporary topics regarding chimeric antigen receptor (CAR) T-cells in multiple myeloma (MM)
Plata, Carlos
core  

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

BMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao, Rui Qu, Zan Dai, Xiqun Jiang, Xu Zhen   +4 more
wiley   +1 more source

Ultrasmall Fe‐curcumin immunomodulators reinvigorate CAR‐T cells to potentiate solid tumor immunotherapy by mitigating cell exhaustion and senescence

BMEMat, EarlyView.
This work discovered a novel research that ultrasmall Fe‐curcumin immunomodulators could reinvigorate CAR‐T cells to potentiate solid tumor immunotherapy by mitigating cell exhaustion and senescence. Abstract CAR‐T cell immunotherapy has achieved exciting success in hematologic malignancies, but the therapeutic efficacy is relatively limited in solid ...
Jiazhi Duan, Yuchan Xue, Miao Zhang, Zihao Zhang, Shiyu Peng, Minghao Sui, Han Ding, Yingying Nie, Yuemin Feng, Le Wang, Tianru Zhang, Mingchuan Yu, He Xia, Hong Liu, Qiang Zhu, Songbo Zhao   +15 more
wiley   +1 more source

Neurological implications of chimeric antigen receptor-T cell therapy. [PDF]

BMJ Neurol Open
Raffoul DG, Roos I, Mulazzani M, Anderson MA, Monif M, Garber J, van der Walt A, Massey J, Kuznetsova V, Nesbitt C, Dowling M, Ruderman I, Lasocki A, Tam CS, Harrison SJ, Kalincik T.   +15 more
europepmc   +1 more source

Real time in vivo efficacy monitoring of desialylation and perforation enhanced immunotherapy of cancer

BMEMat, EarlyView.
A multifunctional nanomedicine is designed to engineer NK cells for enhanced cancer immunotherapy through perforation and desialylation, enabling real‐time monitoring of ATP and GrB levels for precise efficacy assessment. Abstract Efficient enhanced NK cell therapy is of critical importance in the immune treatment of cancer.
Yuanjiao Yang, Yuru Wang, Xuemei Li, Chaoyi Yang, Yuhui Yang, Yanyun Fang, Lin Ding, Yunlong Chen, Huangxian Ju   +8 more
wiley   +1 more source

A Review of Recent Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapy for Hepatocellular Carcinoma. [PDF]

Med Sci Monit
Lv X, Chen X, Ge Y, Si G, Li Y, Li X, Yuan X.   +6 more
europepmc   +1 more source

Integrated spherical nucleic acid nanoreactor mobilizes targeted PD‐L1 proteolysis and cuproptosis for robust breast cancer immunotherapy

BMEMat, EarlyView.
This study provides an integrated spherical nucleic acid nanoreactor (denoted as AMCuD) for targeted PD‐L1 degradation and chemo‐dynamically enhanced cuproptosis to synergically elicit robust immunotherapy against the triple‐negative breast cancer (TNBC) growth, recurrence and metastasis.
Ningxi Li, Honglin Huang, Qianyi Zeng, Li Zeng, Ziman Yang, Jinyang Shen, Shun Li, Hong Yang, Yiyao Liu, Chunhui Wu   +9 more
wiley   +1 more source